The FDA approved Neurontin in 1994 for treatment of partial seizures usually associated with epilepsy. It was later approved for pain management associated with postherpetic neuralgia as a result of shingles.
Shortly after Neurontin appeared on the market, the manufacturer, Pfizer, began intensive marketing of the drug for off-label purposes not approved by the FDA, including bipolar disorder, attention deficit disorder, migraines and drug and alcohol withdrawal.
Pfizer also marketed the drug for use as a first-line monotherapy treatment for epilepsy, which the FDA had previously rejected. Pfizer continued to implement marketing techniques that illegally promoted Neurontin, influencing off-label uses based on unproven claims. These actions may have caused both patients and doctors to be unable to weigh both the benefits and risks of using the drug.
To learn more about legal claims relating to Neurontin, consult an attorney who practices in the area of drugs and medical devices.
Factors Often Involved in Motor Vehicle Accidents According to data collected by the National Highway Traffic Safety Ad... Read More
What Factors Are Involved? | How the Court Determines the Amount Though it's less common than it was generations ago, a... Read More
Taking the Right Steps to Get the Outcome You Want in a Custody Dispute Whether you're currently going through the divo... Read More
How It Works